blood analyz blood test veterinarian
client offer wide rang chemistri
hematolog immunotherapi test
high-definit digit radiographi
digit ultrasound technolog pair
requir disclosur end report
estim way high risk downsid
heska corpor particip annual cl king best idea
confer thursday septemb new york citi see list
concern need invest heavili either
compani investor suspect therefor lower revenu
ep estim although would affect
dcf analysi therefor overal valuat strateg valu
higher ever follow takeout abaxi abaxa zoeti
therefor valuat would requir investor add
takeout premium advis investor remain cautiou near-
term earn potenti reiter neutral rate
stock call despit modest guidanc step-down surpris
stock move follow analyst day zoeti acquisit abaxi
essenti digest anim health ah diagnost
asset avail howev anticip major reduct earn near
term ergo believ stock trade meaning ahead dcf
valuat off-set strateg valu asset negat
fundament valu therefor maintain neutral rate
new product impress new product compani
announc last month concern cost associ
even product develop done third
parti hasnt tradit product develop compani
maintain conservat view aggress product timelin
furthermor sinc showcas envelope-push product analyst
day wouldnt surpris build team even
team focus addit intern valid third-parti equip
like extend convers henri schein
nr ah divis partnership jv outsid unit state
would significantli lower cost intern expans howev
henri schein strateg initi take prioriti
alon think expens infrastructure-heavi approach
necessari understand fuji fujiy nr
restrict chemistri instrument use market
think could overcom restrict prove worthi
partner abroad current model expens intern expans
approach compani offici sign partner jv abroad
avenu first doesnt invest product
intern expans think under-perform top-lin potenti
consequ would get full valu takeout scenario second
compani fulli invest earn hit near term think
stock would suffer ultim model invest heavili
think that right thing
outperform project develop product faster expect
furthermor possibl compani product develop partner
creat good enough product hire build
team intern larger player ah believ fuji restrict
outsid contact could wrong
addit could find low-cost partnership give full control
full diagnost suit sale abroad could becom robust low cost
model adjust number street low wide margin
decreas revenu
respect
compar street respect estim
also significantli lower
ep estim
respect compar
street respect note ep estim street-low
model spend base abaxi abaxi product develop
intern expans year back use proxi
expect somewhat mirror abaxi follow intern expans
product develop although abaxi revenu roughli
vs human health divis roughli
revenu almost complet sold abbott nr
gross margin expect gross margin expans come
mostli improv product mix current lower-
margin ovp imag product segment repres revenu
think howev expand gross margin
would lower abaxi keep
mind abaxi revenu consum model
would still revenu come low-
margin ovp imag segment
 although expect third parti significantli
 heavi lift go assum compani
spend significantli today still less one-
quarter amount abaxi product bring market
less regulatori intens expect compani spend
roughli one-fifth estim
page
 spent less half amount abaxi sale
market less veterinari revenu
abaxi known underpay sale rep major differ
size abaxi salesforc addit intern salesforc
think close align abaxi revenu
although rais revenu
 spend roughli less abaxi even
though much less revenu although assum could
see leverag line conservat go assum
oper leverag think abaxi ad qcr
trio diagnost limit distributor year
abaxi ad line
word potenti acquir follow abaxi takeout spoke
manag consult close everi major acquir
zoeti mar elanco part nr patterson
mwi part nr found abaxi
desir asset acquir abil gener direct sale
core asset outsid unit state although complet sure
partnership work fuji acquir team unanim
question structur agreement fuji
addit acquir potenti acquir mention gross
margin profil abaxi vs despit thought pretti lofti
valuat abaxi enterprise-value-to-gross-margin basi
trade premium metric current valuat exce abaxi
takeout valuat trade ev/gross incom vs abaxi
henri schein/vet first choic base
understand appear complet tie merger
vet first choic diagnost partnership current
outsid scope comment past weve known
henri schein product agnost could ultim help
particularli zoeti tri cut distributor abroad remind us
good relationship zoeti own abaxi
possibl relationship stay solid ultim key
get product abroad put anoth way meaning
upsid ep estim win partnership
valuat trade near histor peak valuat despit top-
line growth moder mid-doubl digit project
mid- high singl digit
page
risk includ relianc distributor regul multipl sole supplier
vet industri macro situat price concess competit
view current cl king meet event calendar coverag univers
page
